Roche gets FDA approval for Alecensa in early lung cancer
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
This facility manufactures APIs & formulations of oncology and non-oncology products.
Fluid bed processes: drying, granulating, and coating in just one product container
Highly effective preservation solutions ensuring the safety and protection of personal care products
New leadership team announced at NATHEALTH Annual General Meeting 2024
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Subscribe To Our Newsletter & Stay Updated